Eli Lilly Shares Reach All-Time High on Strong Weight-Loss Drug Trial Results

TLDR

• LLY ended trading at an all-time high, surpassing a $1 trillion market capitalization once again for the first time since November
• Retatrutide (known as “Reta” in financial circles), an experimental obesity medication targeting three biological pathways, is generating more investor enthusiasm than existing GLP-1 frontrunners
• The Phase 3 TRIUMPH-1 study revealed patients shed an average of 70.3 pounds (28.3% of their body weight) over an 80-week period
• Following the trial data release, Wolfe Research reaffirmed its Outperform rating on LLY and maintained a $1,350 price target
• Lilly also acquired Engage Biologics for up to $202 million to broaden its drug delivery pipeline

---

(SeaPRwire) –   Eli Lilly (LLY) notched its first all-time high close since November, propelling the firm back over a $1 trillion market cap. The stock ended the day at $1,126.80, a 4.05% gain, and has now risen more than 25% from its March 30 low point.

Eli Lilly and Company (LLY)

What’s fueling this surge? Retatrutide—referred to as “Reta” on Wall Street—an unapproved experimental drug.

Retatrutide is Lilly’s next-gen experimental obesity treatment. It acts on three hormone pathways linked to appetite control, blood sugar management, and energy expenditure, setting it apart from Zepbound and Mounjaro, which target only two pathways.

The Phase 3 TRIUMPH-1 trial results underscore why investors are focused on this drug. Patients on the highest dose lost an average of 70.3 pounds (28.3% of body weight) over 80 weeks. Over 45% of participants taking that dose shed at least 30% of their body weight—a milestone Lilly notes is traditionally associated with bariatric surgery outcomes.

Prior findings from May 21 showed higher-BMI participants lost over 30% of their body weight at 104 weeks, alongside improvements in various cardiometabolic risk markers.

What Analysts Are Saying

Wolfe Research called the results a new benchmark for next-generation obesity therapeutics, reaffirming its Outperform rating on LLY and keeping a $1,350 price target. The firm stated the data strengthens Lilly’s position and differentiation in the GLP-1 market.

LLY has gained more than 400% over the past five years, making it one of the clearest growth stories in healthcare.

Novo Nordisk (NVO) also rose 2.15% that day, a sign the market is lifting the broader GLP-1 sector. Amgen (AMGN) and Viking Therapeutics (VKTX) are also in the obesity-drug race, but Lilly remains the player with the largest market-cap weight behind it.

Lilly Broadens Its Pipeline via $202M Acquisition

A day before the TRIUMPH-1 buzz, Lilly announced it had acquired Engage Biologics for up to $202 million. Engage is developing the Tethosome platform, a non-viral DNA delivery technology aimed at solving challenges around potency, tolerability, and repeat dosing.

The deal was structured as an upfront payment plus milestone-based payments tied to development progress.

Ripple effects from Lilly’s run are visible across other sectors. Packaged food, alcohol, and restaurant names continue to face pressure from the broader GLP-1 narrative. Campbell’s (CPB) recently hit historic lows, while Diageo (DEO) and other alcohol brands remain well below their peaks.

For now, the chart has one key level to watch: the old high near $1,100. LLY already cleared it with Wednesday’s close at $1,126.80, putting the stock back in record territory.